American Diabetes Association

Abstract

A simpler dosing regimen may bring the benefits of rapid-acting Insulin tailored to mealtime carbohydrates to a wider population; a lipid-lowering agent offers a glycemic control bonus, and a new oral agent targeting pancreatic islet dysfunction demonstrates broad efficacy, These innovations were presented at key clinical sessions at this year's American Diabetes Association's (ADA's) 66th Annual Scientific Sessions, which took place from June 9 to 13, 2006.